ARTÍCULOS DE SOBERANA 02

DISEÑO, CARACTERIZACIÓN Y ESTUDIOS PRECLÍNICOS

Conformational characterization of the mammalian‑expressed SARS‑CoV‑2 recombinant receptor binding domain, a COVID‑19 vaccine
Molecular Aspects Concerning the Use of the SARS-CoV‑2 Receptor Binding Domain as a Target for Preventive Vaccines
In‑solution buffer‑free digestion allows full‑sequence coverage and complete characterization of post‑translational modifications of the receptor‑binding domain of SARS‑CoV‑2 in a single ESI–MS spectrum
A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies
SARS-CoV‑2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies
Repeat-dose and local tolerance toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats
Design, development and preclinical evaluation of SOBERANA®02: A Cuban vaccine against COVID-19

ESTUDIOS CLÍNICOS

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combinationwith SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children
Progresión de la COVID-19 en trabajadores de una institución de salud cubana, vacunados con el esquema heterólogo de SOBERANA
Estudio de intervención con SOBERANA® en los trabajadores del Centro Nacional de Biopreparados
Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2–11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study
PastoCovac and PastoCovac Plus as protein subunit COVID‑19 vaccines led to great humoral immune responses in BBIP‑CorV immunized individuals
Evaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial
Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response—a prospective, single-arm study
Pediatric and adolescent COVID‐19 vaccination side effects: A retrospective cohort study of the Iranian teenage group in 2021
Farmacovigilancia intensiva de vacunas SOBERANA®02 y Soberana®Plus en población pediátrica en el Centro de Inmunología Molecular
Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children